Delving into the Latest Updates on CLIPS SA with Synapse

Overview

Clinical Study Objective:
To evaluate the tolerability and safety after transplantation of LSCD101 in patients with intractable limbal stem cell deficiency
Study Method:
Subjects who finally meet the inclusion/exclusion criteria results of the subject eligibility evaluation will receive transplantation of the investigational product. Adverse drug reaction will be confirmed during 24 weeks after transplantation.

Start Date31 Jan 2020

Sponsor / Collaborator

CLIPS SA

KCT0004741

/ CompletedPhase 1

Phase I Study to Evaluate Safety of LSCD101(Cultured Autologous Limbal Epithelial Cell Sheet) Transplantation for Limbal Stem Cell Deficiency

Start Date31 Jan 2020

Sponsor / Collaborator

CLIPS SA

TCTR20190325003

/ Not yet recruitingPhase 3

A Multi-national, Multi-center, Randomized, Double-Blind, Active-Controlled, Phase III Study to Investigate the Efficacy and Safety of â€˜GC3107 (BCG Vaccine)â€™ after Intradermal Administration in Healthy Infants

Start Date19 Aug 2019

Sponsor / Collaborator

CLIPS SA

100 Clinical Results associated with CLIPS SA

Login to view more data

0 Patents (Medical) associated with CLIPS SA

Login to view more data

100 Deals associated with CLIPS SA

Login to view more data

100 Translational Medicine associated with CLIPS SA

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data